




Acuitas Therapeutics Inc.

Non Confidential Presentation
May 2026

© 2026 Acuitas. All rights reserved.



Overview



WHO WE ARE

Acuitas is a globally recognized biotechnology company specializing in the **development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP).**

Our LNP has enabled **three world firsts:** Onpattro®, Comirnaty®, and the first personalized CRISPR gene therapy.



WHO WE WORK WITH

- Cutting edge **pharmaceutical & biotechnology** companies
- Leading **academics in universities & institutes**
- **Foundations & NGOs**



HOW WE WORK

As a technology platform provider, we exclusively work in collaboration with partners.

We do not have our own drug development programs – **we are focused on supporting our partners to bring their drug products to patients.**

Applying Our LNP Technology

Gene Modulation

Expression of an **epigenetic editor** to modify gene expression **without changing the genetic code.**

Antibody & Therapeutic Protein Delivery

Expression of **proteins including prophylactic or therapeutic antibodies** to treat current and emerging diseases.

Gene Editing

Expression of a **genome editing** protein to modify gene expression.

Vaccines

Expression of viral or bacterial proteins to generate a protective **immune response.**

Expression of **tumour antigens** (including personalized cancer vaccines).


In Vivo CAR-T

Expression of a Chimeric Antigen Receptor for **in vivo production of CAR-T cells** to treat cancer and autoimmune disease.



Our Partners' Success

Products in Clinic



Clinical Firsts



First Clinically
Approved
**RNA
interference-
based
Medicine**



First Clinically
Approved **mRNA
Vaccine**



First **LNP
enabled
personalized
CRISPR gene
editing therapy**



May 2026: [Ukko Announces First Participant Dosed in Phase 1/2a Clinical Study Evaluating UKK-0018 for Peanut Allergy Treatment](#)



April 2026: [CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors](#)

December 2025: [CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy](#)

November 2025: [CREATE Medicines Announces Positive First-in-Human Results for MT-302](#)



January 2026: [nChroma Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of Epigenetic Silencer CRMA-1001 for Chronic Hepatitis B](#)



January 2026: [Centivax Initiates Phase 1 First-in-Human Clinical Trial of Universal Flu Vaccine](#)



November 2025: [Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting@ Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts](#)



Metagenomi

November 2025: [Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development](#)



Aug 2025: [Beam Therapeutics Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency \(AATD\)](#)



July 2025: [Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the redePHine Phase 1/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary Hyperoxaluria Type 1](#)




Dec 2024: [Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B](#)




Sept 2024: [CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress](#)



Our Approach to Innovation



Our Approach to Innovation




LEGEND cGMP ready + in clinic



In vivo CAR T, Enabled by Targeted LNP (tLNP)

tLNP enables **cell-specific** delivery



tLNP with DARPin
(Athebody™)

tLNP unlock **in vivo** applications in **autoimmune disease and oncology**



Autoimmune
indications with
**inappropriate immune
response**



Oncology indications
**to engage immune
response**

Proof-of-Concept in Non-Human Primates

CREATE CD20 CAR Product Design

T cell-targeting binder

- CD8-specific DARPin (~15kDa) (Athebody™)


mRNA

- Engineered linear mRNA encoding CD20-BBζ CAR

Acuitas LNP Formulation

- Optimized for T cell targeting
- Lipid clinically validated

NHP Study Design




Study	Dose	Schedule
Study 1	0.25 mg/kg	D0, D3, D6

Observations


- Circulating B cell depletion
- Lymphoid tissue and bone marrow-resident B cell depletion
- Safety; well tolerated

Profound Depletion: Circulating & Tissue B Cells



Complete Blood Depletion



Complete Lymphoid Depletion



Confirmed by IHC




Spleen IHC

Best-in-Class Multivalent & Cancer Vaccine Potency


MULTIVALENT VACCINES

Next Generation vaccine LNP show equivalent activity at **5-fold lower dose** vs. **ALC-315®**.



CANCER VACCINES

Acuitas LNP demonstrate **increased abundance & functionality** of antigen-specific CD8 T cells vs. clinical comparator (SM-102).




Acuitas LNP Clinical Comparator

Simplified Manufacture via Pre-Formed Vesicles (PFV)

PFV enables a kit format (2 vials) where mRNA is loaded into empty LNP at point-of-care




mRNA



Empty LNP




mRNA-LNP



For Vaccine Applications (i.e., IM)

PFV achieves equivalent potency to conventional LNP manufacturing methods



For Systemic Applications (i.e., IV)

Accelerating Clinical Entry

Chemistry	Formulation	Analytical	Preclinical
Lipid Design	LNP Formulation & Nucleic Acid Loading	(Bio)analytical Methods Development & Transfer	Pharmacology
Lipid Synthesis	Product Development	Biophysical Characterization	PK / ADME
SAR Analysis	Formulation Optimization		Toxicology
			Immunology

Our Development Lifecycle



CMC	Regulatory
Tech Transfer	(Pre) IND / CTA Review
Manufacturing Scale Up	LNP Positioning to Regulators
	Clinical Safety Profile

Our breadth and depth of capabilities enables end-to-end drug development support.

Why Acuitas?

1 **Best-in-class and First-in-class**

We have unparalleled technology with:

- **First-in-class and best-in-class** drug products commercialized, including Onpattro® and Comirnaty®.
- A broad and **comprehensive IP portfolio**.

2 **Accelerated Clinical Entry**

We understand the importance of early clinical entry.

We provide access to **cGMP-grade lipids**.

Our **expertise in tech transfer and product scale up** de-risks your development program, saving you time and money.

Our partners have initiated **33 clinical trials** in the last 3 years.

3 **Unparalleled Scientific Leadership & Experience**

Working with academic scientists and key opinion leaders we **publish regularly in the top scientific journals**.

Our team is at the cutting edge of scientific discovery.

Our Scientific Leadership

Mechanism of Action

nature



nature

- [Spatial profiling of gene editing by in situ sequencing in mice and macaques \(2025\)](#)
- [Distinct components of nucleoside-modified messenger RNA vaccines cooperate to instruct efficient germinal center responses \(2025\)](#)
- [Molecular fate-mapping of serum antibody responses to repeat immunization \(2023\)](#)

Therapeutic Areas



nature

nature



- [Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease \(2025\)](#)
- [Treatment of a metabolic liver disease in mice with a transient prime editing approach \(2025\)](#)
- [A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels \(2025\)](#)
- [Physiologically based modeling of LNP-mediated delivery of mRNA in the vascular system \(2024\)](#)

Extra-hepatic Application



Science

Science

- [Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke \(2024\)](#)
- [Exploring Mechanisms of Lipid Nanoparticle-Mucus Interactions in Healthy and Cystic Fibrosis Conditions \(2024\)](#)
- [In vivo modification of hematopoietic stem cells by targeted lipid nanoparticles delivering mRNA \(2023\)](#)
- [CAR T cells produced in vivo to treat cardiac injury \(2022\)](#)

Vaccine Improvements

Science

Science


Science

Science Translational Medicine

- [Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates \(2025\)](#)
- [An IL-12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses \(2025\)](#)
- [A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection \(2024\)](#)
- [Computationally designed mRNA-launched protein nanoparticle immunogens as an integrated vaccine platform \(2025\)](#)

For a current list of publications, please visit our website [here](#).

How We Collaborate



*: Shipping costs may apply.

**Let's
Connect**

bd@acuitastx.com
<https://acuitastx.com/>